Table 4.
Muscle quantity related factors in COVID‐19 patients
| Characteristics | PMAI ≤median a | PMAI >median a | P value |
|---|---|---|---|
| Patients (N) | 53 | 60 | |
| Age (years) | 73 (63–84) | 66 (54–78) | 0.001 c |
| Gender (male/female) | 33/20 (62.3/37.7%) | 36/24 (60.0/40.0%) | 0.975 b |
| Body height (cm) | 170 (168–180) | 173 (165–180) | 0.810 d |
| Body weight (kg) | 80 (67–90) | 80 (70–93) | 0.041 c |
| BMI (kg/m2) | 26.1 (23.0–27.8) | 26.8 (23.9–30.6) | 0.024 c |
| BMI (>30 kg/m2) | 12 (22.6%) | 17 (28.3%) | 0.137 b |
| Pre‐existing comorbidities | |||
| Arterial hypertension | 39 (73.6%) | 34 (56.7%) | 0.002 b |
| Cardiovascular disease | 35 (52.8%) | 26 (43.3%) | 0.093 b |
| Diabetes mellitus | 20 (37.7%) | 18 (30.0%) | 0.162 b |
| Chronic respiratory disease | 12 (22.8%) | 11 (18.3%) | 0.161 b |
| Cerebrovascular disease | 16 (30.2%) | 12 (20.0%) | 0.346 b |
| COVID‐19 severity/outcome | 0.088 b | ||
| Uncomplicated | 19 (35.8%) | 25 (41.7%) | |
| Complicated | 13 (24.5%) | 23 (38.3%) | 0.803 b |
| Critical | 21 (39.6%) | 12 (20.0%) | 0.092 b |
| Deceased | 15 (28.3%) | 3 (5.1%) | 0.001 b |
| Medical care | |||
| Hospital care | 53 (100%) | 60 (100%) | 1.000 d |
| Hospital care duration (days) | 19 (11–26) | 12 (7–21) | 0.020C |
| Intensive care | 17 (32.1%) | 12 (20.3%) | 0.290 b |
| Intensive care duration (days) | 25 (14–47) | 13 (8–25) | 0.100 c |
| Invasive ventilation | 14 (26.4%) | 9 (15.3%) | 0.239 b |
| Ventilation duration (days) | 22 (7–39) | 11 (5–22) | 0.217 d |
| Vasopressor therapy | 11 (21.6%) | 7 (11.7%) | 0.313 b |
| Renal replacement therapy | 5 (10.0%) | 4 (7.9%) | |
| ECMO | 3 (5.8%) | 0 (0.0%) | 0.255 d |
| No anticoagulation | 4 (7.5%) | 3 (5.1%) | |
| Prophylaktische LMWH/heparin | 29 (54.7%) | 40 (66.7%) | 0.859 b |
| Therapeutische LMWH/heparin | 20 (37.7%) | 17 (28.3%) | 0.794 b |
| Dexamethasone | 26 (49.1%) | 27 (45.0%) | 0.257 b |
Patient characteristics are presented as median (interquartile range) or number (%).
a
The gender‐specific median PMAI (male: 246.9 mm2/m2, female: 224.1 mm2/m2) derived from the COVID‐19 Cohort I was applied.
b
χ 2 test.
c
Mann–Whitney U test.
d
Student's t test.